The WHO states that 7 out of 100 patients in developed countries and 10 in 100 patients in developing countries acquire at least one hospital-acquired infection (HAI). Likewise, the CDC estimates that around 1 in 31 patients in the U.S. contract at least one HAI at any given time.

Browse detailed report - Hospital-Acquired Infection Diagnostics Market Analysis and Demand Forecast Report

Healthcare units use a range of instruments, reagents, and consumables to diagnose hospital-acquired pneumonia and bloodstream, urinary tract infections (UTIs), gastrointestinal infections, and surgical site infections (SSIs) via immunoassay, urinalysis, and molecular diagnostic tests. In the coming years, medical professionals will increasingly rely on molecular diagnostics due to the growing public awareness about personalized medicine, and rising number of projects related to biomarker identification. Emerging economies around the world are expected to show a high inclination for this test type due to the growing public awareness regarding HAIs.

Globally, the North American region will emerge as the leader of the hospital-acquired infection diagnostics market in the foreseeable future, owing to its improved healthcare sector, a surge in the number of patients affected by nosocomial infections, and a strong presence of prominent diagnostic product manufacturers in the U.S. and Canada. Additionally, the mounting geriatric population and soaring public awareness about HAIs will propel the use of such medical products.

Thus, the rising cases of HAIs and burgeoning geriatric population will facilitate the use of products to help diagnose them worldwide.